Fortified bread trimmed blood-sugar swings in a small type 2 diabetes trial

Swapping an ordinary loaf for one heavily fortified with fibre and protein produced a small improvement in blood-sugar control in adults with type 2 diabetes, according to a short randomised crossover trial published in Diabetes, Obesity and Metabolism [s1]. The effect showed up on continuous glucose monitors over two weeks, but the markers that doctors usually track over months — long-term blood sugar, weight and cholesterol — did not change. It is a modest, early result about a single food, not a prescription.

What the trial did

Researchers gave free-living adults with type 2 diabetes a commercially produced high-fibre, high-protein bread — fortified with lupin flour, pea protein and wheat fibre — or a refined-grain control bread, each for two weeks, in random order, with a two-week washout in between [s1]. The fortified loaf contained 8.1 g of fibre and 19.5 g of protein per 100 g, against 2.9 g of fibre and 10.4 g of protein per 100 g in the control [s1].

During each two-week block, participants wore a continuous glucose monitor and gave fasting blood samples; the team also measured body size and collected three-day food diaries [s1]. The primary outcome was postprandial glycaemia — the rise in blood sugar after meals — captured as the incremental area under the glucose curve across all meals [s1].

Thirty-three adults were randomised (mean age 57.9 years, body-mass index 33.1, HbA1c 60.1 mmol/mol), and 31 completed both arms [s1]. Reported energy intake was similar on the two breads, while fibre and protein intakes were higher during the fortified-bread fortnight [s1].

What it found

Compared with the control bread, the fortified loaf lowered the all-meal glucose area under the curve by 21 mmol/L·min (95% confidence interval −39 to −3) [s1]. It also nudged up time in range — the share of the day spent within target glucose limits — by 4.1 percentage points (2.2 to 6.1), cut time above range by 4.3 points (−6.3 to −2.4), and reduced a measure of glucose variability [s1]. Time in range is the yardstick an international consensus group set out as a practical goal for continuous monitoring, where more time in band generally tracks with better control [s2].

Blood pressure also fell: systolic pressure by 7.2 mmHg (−11.2 to −3.2) and diastolic by 7.2 mmHg (−9.9 to −4.6) [s1]. The authors conclude that reformulating a staple food with fibre and protein is "a practical and scalable strategy" manufacturers could use to support diabetes management [s1].

The limits worth keeping in view

Several features of the design keep this in the "promising signal" category rather than settled advice. The trial was small — 33 people — and ran for just two weeks per bread, far too short to move HbA1c, the three-month average of blood sugar [s1]. Indeed, the study found no differences between the breads in body size, blood lipids or C-reactive protein, an inflammation marker [s1]. The glucose improvements were measured by monitor, a surrogate for the hard outcomes — heart attacks, kidney disease — that ultimately matter in diabetes, and short crossover studies of diet are prone to the play of chance and to participants eating differently when they know they are being watched.

The blood-pressure drops are eye-catching for a food study, but with so few participants and a two-week window they should be read cautiously until larger and longer trials test whether they persist. The work was supported by the Otago Medical Research Foundation [s1].

What it means

The honest reading is narrow. Over two weeks, a loaf engineered to carry roughly three times the fibre and nearly double the protein of ordinary bread shaved the post-meal glucose rise and bought a little more time in range in people with type 2 diabetes — without touching their weight or cholesterol [s1]. That is consistent with long-standing dietary advice to favour higher-fibre, higher-protein staples, and it hints that reformulating everyday foods, rather than asking people to overhaul their diets, could be one lever for manufacturers and public-health planners.

What it does not show is that this bread lowers long-term blood sugar, prevents complications, or works the same way outside a monitored trial. Anyone with diabetes considering a change to their staple foods should treat this as a reason to ask their clinician or dietitian about fibre and protein, not as evidence that a particular product will manage the condition. Larger trials running for months, measuring HbA1c and clinical outcomes, are the next step before any firmer claim is warranted.